Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant

J Clin Oncol. 1994 May;12(5):998-1004. doi: 10.1200/JCO.1994.12.5.998.

Abstract

Purpose: This study analyses the risk of cardiac complications and its individual predictability in bone marrow transplantation (BMT).

Patients and methods: One hundred seventy patients undergoing allogeneic (n = 150) or autologous (n = 20) BMT were evaluated by physical examination, history, rest and exercise ECG, chest x-ray, two-dimensional echocardiography, and radionuclide ventriculography (RNV) before BMT, and monitored for 3 months thereafter.

Results: Following BMT, cardiac toxicity occurred in eight patients (4.7%). Three patients (1.8%) developed life-threatening toxicity (pericardial effusion and left ventricular failure, n = 2; sudden cardiac arrest, n = 1). Thirty-eight patients (22%) had pathologic findings before BMT. In 22 patients, left ventricular ejection fraction (EF) determined by RNV was reduced to less than 55%. This was the only abnormality in 17 patients and was generally mild, with a lowest EF of 42%. There was no correlation between overall results of cardiologic evaluation before BMT and cardiac toxicity. Cardiotoxic events occurred more frequently in patients with a reduced EF (P < .05). However, this was restricted to minor cardiac events. Life-threatening cardiac toxicity was not significantly increased in patients with pathologic results before BMT. Moreover, none of the patients with an EF less than 50% developed cardiac toxicity.

Conclusion: Life-threatening cardiac toxicity is rare after BMT, occurring in less than 2% of all patients. Although the occurrence of cardiac toxicity is correlated with a reduction of EF before BMT, life-threatening cardiac toxicity cannot be predicted in individual patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / therapeutic use
  • Arrhythmias, Cardiac / etiology
  • Bone Marrow Transplantation / adverse effects*
  • Combined Modality Therapy
  • Female
  • Heart / physiology*
  • Heart Arrest / etiology
  • Heart Diseases / etiology*
  • Heart Failure / etiology
  • Heart Function Tests
  • Hematologic Diseases / therapy
  • Humans
  • Leukemia / therapy
  • Lymphoma / therapy
  • Male
  • Middle Aged
  • Pericardial Effusion / etiology
  • Predictive Value of Tests
  • Risk
  • Transplantation, Autologous
  • Transplantation, Homologous

Substances

  • Antineoplastic Agents